741287-82-1

Basic information

• Product Name: 2(1H)-Pyridinone,5-methoxy-,hydrazone(9CI)
• Synonyms: 2(1H)-Pyridinone,5-methoxy-,hydrazone(9CI);2-Hydrazinyl-5-methoxypyridine;3-Methoxy-6-(hydrazino)pyridine;(5-Methoxy-pyridin-2-yl)-hydrazine
• CAS NO: 741287-82-1
• Molecular Formula: C₆H₉N₃O
• Molecular Weight: 139.16
• Product Categories: PYRIDINE
• Mol File: 741287-82-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 284℃
• Flash Point: 126℃
• Appearance: /
• Density: 1.23
• PKA: 9.48±0.70(Predicted)
• CAS DataBase Reference: 2(1H)-Pyridinone,5-methoxy-,hydrazone(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone,5-methoxy-,hydrazone(9CI)(741287-82-1)
• EPA Substance Registry System: 2(1H)-Pyridinone,5-methoxy-,hydrazone(9CI)(741287-82-1)

Safety Data

• Hazardous Substances Data: 741287-82-1(Hazardous Substances Data)

Usage

Chemical structure

A pyridinone ring with a 5-methoxy substitution and a hydrazone functional group.

Usage

Commonly used as a reagent in organic synthesis and chemical research.

Importance

Hydrazones are important intermediates in numerous organic reactions and have applications in pharmaceuticals, dyes, and pesticides.

Specific properties and uses

Depend on further investigations and studies.

Upstream product

• 139585-48-1 2-chloro-5-methoxypyridine 
• 105170-27-2 2-bromo-5-methoxypyridine 

Downstream Products

• 741287-84-3 ethyl 1-(6-methoxypyridin-3-yl)-5-phenyl-1H-pyrazole-3-carboxylate 

Relevant articles and documents

UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS

The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.